Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
This study has been completed.
Study NCT00031733 Information provided by National Cancer Institute (NCI)
First Received: March 8, 2002 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Intraocular Melanoma
Melanoma (Skin)
Additional conditions recognized in this trial
Eye Neoplasms
Melanoma
More general conditions related to this trial
Eye Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
MART-1 antigen
gp100 antigen
incomplete Freund's adjuvant
recombinant interleukin-12
sargramostim
tyrosinase peptide
alum adjuvant
adjuvant therapy
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
Aluminum sulfate
Freund's Adjuvant
Interleukin-12
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
USC/Norris Comprehensive Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
